The Top Biosimilars Interviews of 2017

The Center for Biosimilars Staff

2017 brought a number of notable guests to The Center for Biosimilars®. Here are the most-watched interviews of the year.

2017 brought a number of notable guests to The Center for Biosimilars®. Below are the most-watched interviews of the year:

Number 5: Marcus H. Snow, MD, Assistant Professor Rheumatology, University of Nebraska, discusses the recent launch of a new biosimilar infliximab, Renflexis, in the United States.

Number 4: Brandon Shank, PharmD, MPH, BCOP, Clinical Pharmacy Specialist, discusses the importance of pharmacist education on biosimilar treatments.

Number 3: Joseph Fuhr, PhD, explains why biosimilars could bring on brand-to-brand competition.

Number 2: Angus Worthing, MD, FACR, FACP, discusses the benefits of biosimilar medicines.

Number 1: Ha Kung Wong, JD, Partner at Fitzpatrick, Cella, Harper and Scinto, discusses incentives for biosimilar applicants to engage in the BPCIA "patent dance" after the Supreme Court's ruling in Sandoz v Amgen.